Literature DB >> 23816419

Risks associated with the transfusion of various blood products in aortic valve replacement.

Henrik Bjursten1, Faleh Al-Rashidi, Alain Dardashti, Björn Brondén, Lars Algotsson, Per Ederoth.   

Abstract

BACKGROUND: Patients undergoing cardiac operations often require transfusions of red blood cells, plasma, and platelets. From a statistical point of view, there is a significant collinearity between the components, but they differ in indications for use and composition. This study explores the relationship between the transfusion of different blood components and long-term mortality in patients undergoing aortic valve replacement alone or combined with revascularization.
METHODS: A retrospective single-center study was performed including 1,311 patients undergoing aortic valve replacement. Patients who received more than 7 units of red blood cells, those who died early (7 days), and emergency cases were excluded. Patients were monitored for up to 9.5 years. A broad selection of potential risk factors were analyzed using Cox proportional hazards regression, where transfusion of red blood cells, plasma, and platelets were forced to remain in the model.
RESULTS: The transfusion of red blood cells was not associated with decreased long-term survival (hazard ratio [HR], 1.01; p = 0.520) nor was the transfusion of platelets (HR, 0.946; p = 0.124); however, the transfusion of plasma was (HR, 1.041; p < 0.001). All HRs are per unit of blood product transfused. No increased risk was found for patients undergoing a combined procedure.
CONCLUSIONS: No significant risk for long-term mortality was associated with transfusion of red blood cells during the study period. However, the transfusion of plasma was associated with increased mortality.
Copyright © 2013 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  18; ALT; AVR; BMI; C-reactive protein; CABG; CCS; CI; COPD; CPB; CRP; Canadian Cardiovascular Society; HR; IABP; ICU; LVEF; MDRD; Modified Diet in Renal Disease; NYHA; New York Heart Association; PCI; PLA; PVD; RBC; RIFLE; TRALI; TRC; alanine aminotransferase; aortic valve replacement; body mass index; cardiopulmonary bypass; chronic obstructive pulmonary disease; confidence interval; coronary artery bypass grafting; eGFR; estimated glomerular filtration rate; hazard ratio; intensive care unit; intraaortic balloon pump; left ventricular ejection fraction; percutaneous coronary intervention; peripheral vascular disease; plasma; platelets; red blood cell; risk-injury-failure-loss-end stage; transfusion-related acute lung injury

Mesh:

Year:  2013        PMID: 23816419     DOI: 10.1016/j.athoracsur.2013.04.053

Source DB:  PubMed          Journal:  Ann Thorac Surg        ISSN: 0003-4975            Impact factor:   4.330


  4 in total

1.  Fibrinogen concentrate as first-line therapy in aortic surgery reduces transfusion requirements in patients with platelet counts over or under 100×10(9)/L.

Authors:  Cristina Solomon; Niels Rahe-Meyer
Journal:  Blood Transfus       Date:  2014-10-23       Impact factor: 3.443

2.  Demographic and epidemiologic characterization of transfusion recipients from four US regions: evidence from the REDS-III recipient database.

Authors:  Matthew S Karafin; Roberta Bruhn; Matt Westlake; Marian T Sullivan; Walter Bialkowski; Gustaf Edgren; Nareg H Roubinian; Ronald G Hauser; Daryl J Kor; Debra Fleischmann; Jerome L Gottschall; Edward L Murphy; Darrell J Triulzi
Journal:  Transfusion       Date:  2017-10-24       Impact factor: 3.157

3.  The role of plasma gelsolin in cardiopulmonary bypass induced acute lung injury in infants and young children: a pilot study.

Authors:  ShanShan Shi; Chi Chen; DongYan Zhao; XiWang Liu; BaoLi Cheng; ShuiJing Wu; Ru Lin; LinHua Tan; XiangMing Fang; Qiang Shu
Journal:  BMC Anesthesiol       Date:  2014-08-07       Impact factor: 2.217

4.  Non-Inferiority of Sutureless Aortic Valve Replacement in the TAVR Era: David versus Goliath.

Authors:  Alina Zubarevich; Marcin Szczechowicz; Lukman Amanov; Arian Arjomandi Rad; Anja Osswald; Saeed Torabi; Arjang Ruhparwar; Alexander Weymann
Journal:  Life (Basel)       Date:  2022-06-29
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.